Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts.

[1]  L. Arenillas,et al.  Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome , 2008 .

[2]  H. Ehrlich,et al.  Requirements for Co-Stimulation in T-Cell Dependent and T-Cell Independent Re-Stimulation of FVIII-Specific Memory B Cells , 2008 .

[3]  J. Bennett.  Consensus statement on iron overload in myelodysplastic syndromes , 2008, American journal of hematology.

[4]  J. Issa,et al.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System , 2008, Cancer.

[5]  Emanuele Angelucci,et al.  Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias , 2008, Haematologica.

[6]  H. Leitch.  Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. , 2007, Leukemia research.

[7]  S. Goldberg.  Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. , 2007, Leukemia research.

[8]  A. Stamatoullas,et al.  Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM. , 2007 .

[9]  Y. Eshet,et al.  No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique , 2007, American journal of hematology.

[10]  D. Pennell,et al.  Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions , 2007, British journal of haematology.

[11]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Nathan,et al.  Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload , 2007 .

[13]  D. Pennell,et al.  Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox). , 2005 .

[14]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Dimitrov,et al.  Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. , 2005, Leukemia research.

[16]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[17]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[18]  Z. Zemanová,et al.  A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. , 2003, Leukemia research.

[19]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[20]  J. Porter.  Practical management of iron overload , 2001, British journal of haematology.

[21]  A. Hoffbrand,et al.  Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.

[22]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[24]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[25]  R. Gleason,et al.  Clinical consequences of acquired transfusional iron overload in adults. , 1981, The New England journal of medicine.

[26]  W. Roberts,et al.  Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.

[27]  H. Kantarjian,et al.  A prognostic score for patients with lower risk myelodysplastic syndrome , 2008, Leukemia.

[28]  D. Bowen,et al.  Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? , 2001, Leukemia research.